Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed this Form 6-K for the month of January 2026. The filing serves to report a material corporate announcement made to the Australian Securities Exchange on January 12, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is an increase in the Company's ownership stake in Radiopharm Ventures. As of the announcement date, Radiopharm Theranostics Limited increased its ownership in Radiopharm Ventures to 87.5%.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the specific ownership change noted above.
Investor Verification Checklist
- Verify the exact terms and valuation of the transaction that led to the 87.5% ownership stake in Radiopharm Ventures.
- Confirm the financial impact of this increased ownership on the consolidated financial statements.
- Review the attached Public Notice (Exhibit 99.1) for details on the remaining 12.5% equity structure.